ASAIO 2026: MagAssist’s Platform-Based Life Support Solutions Gain International Recognition

Jun 26, 2026 20:16 CST Updated 20:16

magAssist

Developer of Extracorporeal Artificial Heart Devices

From June 17 to 20, 2026, the ASAIO Annual Conference 2026, a prestigious academic conference in the field of international artificial organs and mechanical circulatory support, was held in Florida, USA. ASAIO (American Society for Artificial Internal Organs) is one of the most influential academic organizations globally in the fields of artificial organs and mechanical circulatory support (MCS), having long led the development direction of cardiopulmonary assist devices, artificial organs, and life-support technologies for critical care.

As a representative innovative enterprise in China’s mechanical circulatory support (MCS) field, magAssist showcased its platform-based life support solutions and multiple original research achievements at the conference. Through thematic reports, academic exchanges, and booth displays, it systematically presented to international peers the latest advancements of Chinese-originated MCS technologies in clinical application, engineering innovation, and platform-oriented development.

During the conference, the magAssist booth attracted numerous cardiac surgeons, critical care specialists, engineering scholars, and industry partners from Europe, the Americas, the Middle East, and the Asia-Pacific region for discussions. Many international experts engaged in in-depth discussions on the NyokAssist® percutaneous ventricular assist device, the MoyoAssist® fully magnetically levitated extracorporeal ventricular assist device, and the BreathMo® ECMO platform, as well as the future direction of multi-organ life support. They expressed strong interest in magAssist’s platform-based product portfolio and its innovative technological pathways.

ASAIO 2026

China Original# Evidence-Based Innovation in ResearchResearch Debuts on the International Stage

Zhongshan Hospital Releases SAVE-PCI Study in the Field of High-Risk PCI

Key Evidence-Based Evidence

At this conference, the team from Zhongshan Hospital Affiliated to Fudan University released the results of the SAVE-PCI prospective randomized controlled study.

This study was jointly conducted by 11 centers in China, enrolling a total of 236 patients undergoing high-risk percutaneous coronary intervention (PCI). Using a 1:1 randomized design, the study compared the clinical efficacy of NyokAssist® versus intra-aortic balloon counterpulsation (IABP) for hemodynamic support during high-risk PCI. It represents one of the pivotal randomized controlled trials in the field of domestically developed percutaneous ventricular assist devices (pVADs) in China. The results showed that the 30-day major adverse cardiac and cerebrovascular events (MACCE)-free survival rate was 93.1% in both groups, successfully meeting the prespecified non-inferiority endpoint. No major vascular complications or device-related serious adverse events were observed.

As a high-risk PCI leadAs a key evidence-based study in the field, SAVE-PCI provides high-level clinical evidence for the application of NyokAssist® in short-term circulatory support during complex interventional procedures.It further demonstrates the continuous progress of China's mechanical circulatory support research in the construction of evidence-based medicine systems and international academic exchanges.

ASAIO 2026

Platform-Based Pipeline Layout:

Unified Platform Covering the Full Cycle of Critical Care Circulatory/Cardiopulmonary Support

In the Industry Updates session, the founder of magAssistDr. Xu BolingShared insights on the company’s platform-based strategy for mechanical circulatory support. Dr. Xu Boling introduced that magAssist is building a modular life-support system based on a unified control platform. Through flexible combination and rapid switching of different support modules, it achieves continuous life-support management from the catheterization lab and operating room to the intensive care unit, meeting patients’ support needs across different disease stages and treatment scenarios.

Currently, the company has established three major product pipelines:

NyokAssist®：9Fr foldable percutaneous ventricular assist device, suitable for short-term circulatory support in high-risk PCI, has received FDA Breakthrough Device designation;
MoyoAssist®：The fully magnetically levitated extracorporeal ventricular assist device provides short- to medium-term circulatory support and has been approved by the NMPA for the supportive treatment of cardiogenic shock.
BreathMo® ECMO：Utilizes a unified fully magnetically levitated pump platform to meet the requirements for combined cardiopulmonary support.

In the future, the platform will gradually expand into other areas such as organ perfusion. Leveraging a unified hardware and control architecture, it aims to build an integrated life support platform covering multi-organ support, providing more comprehensive, efficient, and continuous holistic solutions for critically ill patients.

ASAIO 2026

Digital Twin and Intelligent Interaction Technologies Demonstrate Engineering Innovation Capabilities

Vice President, magAssistMr. Yan YifanIn the bioengineering special topic, two engineering innovations were introduced: digital twin-based modeling for circulatory support and a unified GUI interaction system. Related research leverages digital simulation to assist in parameter optimization, establishing a standardized operational framework that covers ECMO, ventricular assist devices, and combined support scenarios, thereby providing a new technical pathway for the future development of intelligent and standardized mechanical circulatory support systems.

ASAIO 2026

International Exchanges Continue to Deepen

China's Original MCS Technology Accelerates Its Global Expansion

As one of the most important academic platforms in the field of global mechanical circulatory support, ASAIO is not only a key window for showcasing cutting-edge research findings but also a vital stage for in-depth exchange among global clinical experts, research institutions, and industrial innovation forces.

During the conference, magAssist further elevated the international academic and industrial profile of China’s original mechanical circulatory support technology through a concentrated showcase of its original clinical research, platform-based product portfolio, and digital engineering innovations. The booth attracted continuous exchanges and discussions among experts, scholars, clinical teams, and industry partners from multiple countries and regions, fully demonstrating the strong interest of the international market in next-generation life support technologies and platform-based solutions.

Driven by clinical needs, powered by technological innovation, and connected through global collaboration, magAssist is continuously advancing the international development of China’s original mechanical circulatory support technology. In the future, the company will further deepen global clinical cooperation and academic exchange, bringing more innovative achievements to the international stage and providing more comprehensive, efficient, and accessible life-support solutions for critically ill patients worldwide.

Disclaimer: NyokAssist® and BreathMo® are currently intended for research and academic exchange purposes only. They have not yet been approved by the National Medical Products Administration (NMPA) and are not sold in any country or region.

-END-